Rigel Pharmaceuticals (RIGL) Set to Announce Earnings on Tuesday

Share on StockTwits

Rigel Pharmaceuticals (NASDAQ:RIGL) is scheduled to be releasing its earnings data after the market closes on Tuesday, August 4th. Analysts expect Rigel Pharmaceuticals to post earnings of ($0.13) per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Rigel Pharmaceuticals (NASDAQ:RIGL) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported $0.13 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.13. Rigel Pharmaceuticals had a negative return on equity of 40.15% and a negative net margin of 27.39%. The firm had revenue of $55.76 million during the quarter, compared to analyst estimates of $56.94 million. On average, analysts expect Rigel Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

RIGL opened at $2.30 on Friday. The business has a 50 day moving average price of $2.22 and a 200 day moving average price of $2.03. Rigel Pharmaceuticals has a twelve month low of $1.23 and a twelve month high of $5.24. The company has a debt-to-equity ratio of 0.35, a quick ratio of 3.68 and a current ratio of 3.73. The firm has a market cap of $407.94 million, a P/E ratio of -14.38 and a beta of 1.26.

Several research firms recently weighed in on RIGL. HC Wainwright restated a “buy” rating and issued a $8.00 target price on shares of Rigel Pharmaceuticals in a report on Thursday, July 9th. JPMorgan Chase & Co. reduced their target price on Rigel Pharmaceuticals from $7.00 to $6.00 and set an “overweight” rating for the company in a report on Wednesday, May 27th. Zacks Investment Research upgraded Rigel Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday. BidaskClub lowered Rigel Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, July 28th. Finally, ValuEngine lowered Rigel Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, July 14th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $6.00.

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc, a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company's clinical programs include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Phase III clinical study for autoimmune hemolytic anemia.

Featured Article: What are some reasons analysts would give stocks a buy rating?

Earnings History for Rigel Pharmaceuticals (NASDAQ:RIGL)

Receive News & Ratings for Rigel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

International Consolidated Airlns Grp  Rating Reiterated by Goldman Sachs Group
International Consolidated Airlns Grp Rating Reiterated by Goldman Sachs Group
Insider Selling: Meritage Homes Corp  EVP Sells 7,000 Shares of Stock
Insider Selling: Meritage Homes Corp EVP Sells 7,000 Shares of Stock
Inflarx  Rating Increased to Buy at Zacks Investment Research
Inflarx Rating Increased to Buy at Zacks Investment Research
TheStreet Lowers Alexion Pharmaceuticals  to C
TheStreet Lowers Alexion Pharmaceuticals to C
A. O. Smith  Raised to “B” at TheStreet
A. O. Smith Raised to “B” at TheStreet
Apollo Global Management  Upgraded to B at TheStreet
Apollo Global Management Upgraded to B at TheStreet


© 2006-2020 Ticker Report